Article

Pfizer Purchases PowderMed

Pfizer has agreed to purchase PowderMed (London, England, www.powdermed.com), a British company that develops DNA-based vaccines.

Pfizer has agreed to purchase PowderMed (London, England, www.powdermed.com), a British company that develops DNA-based vaccines. The company has developed a proprietary needle-free delivery system that delivers DNA-coated microscopic gold particles into the skin using pressurized helium gas. The particles penetrate the epidermal layer of the skin, activating cells that in turn trigger an immune response.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
© 2025 MJH Life Sciences

All rights reserved.